U.S. Markets open in 5 hrs 6 mins

NuVasive, Inc. (NUVA)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
53.54-4.26 (-7.37%)
At close: 4:00PM EDT
People also watch
WMGIOFIXNXTMPODDMASI
  • W
    Wokeupintime
    Wokeupintime

    Who is Glasshouse Research? http://www.glasshouseresearch.com/about.html
    From the appearance of the above, it only lists a total of four (4) research reports, and from viewing its website Glasshouse does not appear to have much going on nor much history. So the question becomes - whose report on Nuvasive should investors rely upon? Should it be Glasshouse?

    After today's drop the Motley Fool gave this analysis:
    NuVasive deals with criticism
    Finally, shares of NuVasive dropped 7%. The maker of minimally invasive surgical systems focused on spinal procedures was the subject of a negative research report from short-selling analyst GlassHouse Research, which points to recent executive departures and what it calls "accounting irregularities" in arguing that the stock is too highly valued compared to better-established players in the medical device space. GlassHouse claims that an appropriate target price for NuVasive stock would be less than half its current price, but the smaller magnitude of today's drop suggests that most shareholders aren't taking the allegations particularly seriously.

    About
    ​GlassHouse Research is made up of forensic accountants/analysts that have worked for prominent hedge funds on Wall Street as well as boutique forensic accounting firms. Our purpose is to expose...
    www.glasshouseresearch.com
  • W
    Wokeupintime
    Wokeupintime
    Zacks TAZR 9/18/17 report said -
    This morning, Cowen analyst Joshua Jennings issued a report citing that NuVasive shares reflect most investor concerns. Jennings said concerns regarding US spine volumes, insurers push-back, guidance, weather impact, and the CFO departure were all priced-in. Jennings expects investors to begin to focus on the LessRay system, new products, new salespeople, and new surgeon customers, which will drive a recovery in shares. The analyst rates NuVasive an Outperform with an $83 price target.

    I think this is good place to catch a turn in a fundamentally sound medical technology company.
  • W
    Wokeupintime
    Wokeupintime
    Another positive article - Seeking Apha - Stephen Simpson, CFA 9/18/17 A Window Has Opened For NuVasive. Looking for high 60's.
    A Window Has Opened For NuVasive
    NuVasive has sold off significantly on senior management changes, an OIG subpeona, and concerns about volume weakness in the U.S. spine market, creating a rare
    seekingalpha.com
  • L
    Long Term
    Long Term
    Glasshouse is looking for a $24 price target - they think there are tons of accounting issues.
  • W
    Wokeupintime
    Wokeupintime

    It says Glasshouse is a short seller. Here is another article claiming Nuva is oversold. Yesterday Zacks TAZR fund recommended a buy and bought at $58. Go figure!
    http://www.nasdaq.com/article/nuvasive-becomes-oversold-nuva-cm847883

  • M
    Mackenzie
    Mackenzie

    Woah! I just got an awesome alert from https://awesomepennystocks1.blogspot.com/. NUVA has been okay but its moving so slow.... .

    Penny Stocks
    awesomepennystocks1.blogspot.com
  • A
    Allison
    Allison
    Is it time to make a move on NUVA? Do you guys find it difficult to know when to buy or sell something? I prefer to get my stocks from Awe-Some.Sto-ck.s.
  • l
    larryh
    larryh
    What the #*@!! is going on with this stock?
  • B
    Bryan
    Bryan
    Big Galning, Low-Prlced NASDAQ and NYSE Alerts ---> PennyStocklOl.org
  • c
    chieu
    chieu
    this stock should be go back to $78.00 soon ..
  • R
    Rodolph
    Rodolph

    Found a great no fee daytrading newsletter, vist www.PennySt0ckl0l.org and sign up...so glad I did

  • B
    Bernie
    Bernie

    Found a great no fee daytrading newsletter, vist www.PennySt0ckl0l.org and sign up...so glad I did

  • B
    BeBo
    BeBo

    http://www.qmed.com/mpmn/medtechpulse/adverse-events-tied-first-its-kind-spinal-device?page=6

    Adverse Events Tied to First of Its Kind Spinal Device | Qmed
    www.qmed.com
  • S
    Stkpicker
    Stkpicker
    When you have such an expensive stock, any concern will crater it. The exit of the president and COO, along with the CFO spells big trouble. They have plenty of tough competitors who can continue to eat their lunch. Stay away until stock is $42 or 21x earnings.
  • S
    ST PANCAKE
    ST PANCAKE
    Trust me this is a very good short. Just ask the employees.
  • L
    Long Term
    Long Term
    2017 guidance is for $1.13 GAAP - why is the stock over $60?
  • L
    Lori
    Lori
    I think NUVA is due for a pullback. What are your thoughts? check out AWE-some.Stock.s, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
  • R
    Rodney
    Rodney
    this company is clueless they are wasting more money on deployment and recruitment of internal talent that does nothing but cost them money....they will invest $20m this year and commit to that number for three years to secure $7m in sales. Management is over its head and looking for the stryker life boat
  • Y
    Yahoo Finance Insights
    Yahoo Finance Insights
    NUVA reached a new All Time High at 80.71
  • Y
    Yahoo Finance Insights
    Yahoo Finance Insights
    NUVA reached a new All Time High at 79.08